Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment
This study has been completed.
Sponsor:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01613690
First received: June 5, 2012
Last updated: NA
Last verified: June 2012
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to see how the body processes and gets rid of NVA237 in people who have impaired kidney function compared to people whose kidney function is normal.
| Condition | Intervention | Phase |
|---|---|---|
|
Renal Impairment |
Drug: NVA237 |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Pharmacokinetics Study Intervention Model: Parallel Assignment Masking: Open Label |
| Official Title: | An Open Label, Non-randomized, Parallel-group Study to Characterize and Compare the Pharmacokinetics, Safety, and Tolerability of a Single Dose of NVA237 in Subjects With Mild, Moderate, Severe and End-stage Renal Impairment With That in Matched Healthy Control Subjects |
Resource links provided by NLM:
Further study details as provided by Novartis:
Primary Outcome Measures:
- Concentration of NVA2105 using PK parameter of primary interest - area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUClast) [ Time Frame: Day 1, 2, 3, 4 and 5 ] [ Designated as safety issue: No ]Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237
- Concentration of NVA2105 using PK parameter of primary interest - maximum plasma concentration (Cmax) [ Time Frame: Day 1, 2, 3, 4 and 5 ] [ Designated as safety issue: No ]Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237
- Concentration of NVA2105 using PK parameter of primary interest - renal clearance (CLR) [ Time Frame: Day 1, 2, 3, 4 and 5 ] [ Designated as safety issue: No ]Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237
- Concentration of NVA2105 using PK parameter of secondary interest - time to Cmax (Tmax) [ Time Frame: Day 1, 2, 3, 4 and 5 ] [ Designated as safety issue: No ]Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237
- Concentration of NVA2105 using PK parameter of secondary interest - AUC extrapolated to infinity (AUCinf) [ Time Frame: Day 1, 2, 3, 4 and 5 ] [ Designated as safety issue: No ]Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237
- Concentration of NVA2105 using PK parameter of secondary interest - terminal elimination half-life, determined from plasma concentrations and urinary excretion rates (T1/2) [ Time Frame: Day 1, 2, 3, 4 and 5 ] [ Designated as safety issue: No ]Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237
- Concentration of NVA2105 using PK parameter of secondary interest - apparent systemic clearance (CL/F) [ Time Frame: Day 1, 2, 3, 4 and 5 ] [ Designated as safety issue: No ]Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237
- Concentration of NVA2105 using PK parameter - amount excreted into the urine from time 0 to 96 h post-dose (Ae0-96h) [ Time Frame: Day 1, 2, 3, 4 and 5 ] [ Designated as safety issue: No ]Samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Urine, Analyte: NVA237
- Concentration of NVA2105 using PK parameter - T1/2 [ Time Frame: Day 1, 2, 3, 4 and 5 ] [ Designated as safety issue: No ]Samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Urine, Analyte: NVA237
- Concentration of NVA2105 using PK parameter - CLR [ Time Frame: Day 1, 2, 3, 4 and 5 ] [ Designated as safety issue: No ]Samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Urine, Analyte: NVA237
Secondary Outcome Measures:
- Change in effect of dialysis in End-stage subjects requiring dialysis (ESRD) using PK parameter Cmax [ Time Frame: Day 1 of each treatment period ] [ Designated as safety issue: Yes ]Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237
- Change in effect of dialysis in End-stage subjects requiring dialysis using PK parameter AUClast [ Time Frame: Day 1 of each treatment period ] [ Designated as safety issue: Yes ]Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237
- Safety and tolerability of a single inhalation dose of 100μg NVA237 in subjects with mild, moderate, severe, and end-stage renal impairment [ Time Frame: Reviewed during each study visit ] [ Designated as safety issue: Yes ]Adverse events will be based on evaluation of physical signs, electrocardiograms and clinical laboratory assessments
| Enrollment: | 48 |
| Study Start Date: | June 2010 |
| Study Completion Date: | November 2010 |
| Primary Completion Date: | November 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Healthy volunteers
control group receiving 100 μg NVA237
|
Drug: NVA237
NVA237 is administered via a BREEZHALER device
|
|
Experimental: Mild renal impairment
(eGFR 50-80 mL/min/1.73m2) receiving 100 μg NVA237
|
Drug: NVA237
NVA237 is administered via a BREEZHALER device
|
|
Experimental: Moderate renal impairment
(eGFR 30-49 mL/min/1.73m2) receiving 100 μg NVA237
|
Drug: NVA237
NVA237 is administered via a BREEZHALER device
|
|
Experimental: Severe renal impairment
(eGFR <30 mL/min1.73m2) receiving 100 μg NVA237
|
Drug: NVA237
NVA237 is administered via a BREEZHALER device
|
|
Experimental: End-stage subjects requiring dialysis (ESRD)
receiving 100 μg NVA237
|
Drug: NVA237
NVA237 is administered via a BREEZHALER device
|
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Male and female subjects age 18 to 70 years of age inclusive.
- Female subjects of childbearing potential must be using two acceptable methods of contraception, (e.g., intra-uterine device plus condom, spermicidal gel plus condom, diaphragm plus condom, etc.), from the time of screening and for the duration of the study, through study completion.
- Subjects must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 17 to 35 kg/m2.
- Able to communicate well with the investigator, to understand and comply with the requirements of the study. Understand and sign the written informed consent
- For renal insufficient subjects only - Subjects must have stable renal disease without evidence of renal progressive disease (for the purpose of this study stable renal disease will be defined as no significant change for 12 weeks).
- For health subjects only - A serum creatinine within the normal range and an eGFR >80 mL/min/1.73 m2.
- For health subjects only - Matched to at least one renal impaired subjects undergoing study by age (±5 years), sex and weight (±10% BMI).
Exclusion Criteria:
- Smokers (use of tobacco products in the previous 3 months). Smokers will be defined as any subject who reports tobacco use and/or who has a urine cotinine ≥ 500 ng/mL. If non-smoking subject are too difficult to recruit, smokers may be allowed to participate in the study provided they commit to smoke no more than 10 cigarettes/day during the days of PK-assessment
- For healthy subjects, use of any prescription drugs, herbal and fitness/bodybuilding/athletic performance-enhancing supplements, within four (4) weeks prior to initial dosing, and/or over-the-counter (OTC) medication, dietary supplements (vitamins included) within two (2) weeks prior to initial dosing
- Recent (within the last three [3] years) and/or recurrent history of autonomic dysfunction (e.g., recurrent episodes of fainting (unless related to water withdrawal during dialysis), palpitations, etc).
- Recent (within the last three [3] years) and/or recurrent history of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated).
- History of multiple and recurring allergies or allergy to the investigational compound/compound class being used in this study.
- Total WBC count which falls outside the range of 3000-12,000/μL, or platelets <100,000/μl at screening.
- History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result.
Other protocol-defined inclusion/exclusion criteria may apply.
Contacts and Locations More Information
No publications provided
| Responsible Party: | Novartis ( Novartis Pharmaceuticals ) |
| ClinicalTrials.gov Identifier: | NCT01613690 History of Changes |
| Other Study ID Numbers: | CNVA237A2105 |
| Study First Received: | June 5, 2012 |
| Last Updated: | June 5, 2012 |
| Health Authority: | Russia: Ministry of Health of the Russian Federation |
Keywords provided by Novartis:
|
Renal impairment NVA237 Pharmacokinetics |
Additional relevant MeSH terms:
|
Renal Insufficiency Kidney Diseases Urologic Diseases |
ClinicalTrials.gov processed this record on May 19, 2013